Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting

BMC Medicine

Editorial

Carlo Selmi¹  Yehuda Shoenfeld² 

[1] Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis, USA;Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, Milan, Italy;Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Israel Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer 52621, Israel;

关键词: Anti-nuclear antibodies;    Atherosclerosis;    Cardiovascular system;    DNA methylation;    microRNA;    Rheumatoid arthritis;    Ultrasonography;   

DOI  :  10.1186/1741-7015-12-50

 received in 2014-03-07, accepted in 2014-03-07,  发布年份 2014

来源: Springer

【 摘 要 】

The recent CORA (Controversies in Rheumatology and Autoimmunity) meeting held in 2013 represented a unique opportunity for rheumatologists to address several topics. Among these, four topics include: (i) the role of epigenetic changes in the pathogenesis of rheumatoid arthritis (RA), as shown by studies in monozygotic twins; (ii) the cardiovascular and atherosclerotic risk in patients with RA treated with biologics; (iii) the use of new biomarkers for the diagnosis and follow-up of RA and other autoimmune diseases, as represented by the new automatic machines for anti-nuclear antibodies detection, or ultrasound imaging to follow RA progression; and (iv) the latest guidelines on how to use and manage biologic therapies in RA and other autoimmune diseases, such as lupus. In summary, we will herein present these topics of discussion and underline the conclusions obtained by rheumatologists during the 2013 CORA Meeting.

【 授权许可】

CC BY   
© Selmi and Shoenfeld; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.